Eye treatment triumph sends Clearside stock soaring

Clearside Biomedical (Nasdaq: CLSD) looked set to open trading more than 50% up on Monday morning, at around $12.20, after announcing positive top-line results from its Phase III trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.

Suprachoroidal CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCS, which is the space located between the choroid and the outer protective layer of the eye known as the sclera.

The company enrolled 160 patients in a randomized, controlled, masked Phase III pivotal trial called PEACHTREE. Of these, 96 patients received two 4mg doses of suprachoroidal CLS-TA 12 weeks apart, and 64 others underwent sham procedures at the same 12-week interval.